- Advertisement -
Saturday, February 4, 2023
Home News Sorting Out the Flipside

Sorting Out the Flipside

Human beings are known to be good at a ton of different things, and yet the greatest ability you can find their arsenal is that tendency to grow on a consistent basis. This ability, in particular, has allowed us to hit upon some huge milestones, with technology sticking out as a member of the stated group. The reason why technology stands out from the rest is predicated upon its unique skill-set, which introduced us to all those possibilities that we could have never imagined otherwise. However, the whole runner was also, at the same time, inspired by how we applied the stated skills in a real-world setting. The latter component was, in fact, what gave the creation a spectrum-wide presence, including a timely appearance on our healthcare block. Technology’s foray into healthcare was so perfectly timed because it came right when the sector was beginning to struggle against its own obsolete structure. Fortunately, this reality was revamped under the new regime, but even after realizing such a massive feat, the medtech concept will jut continue producing all the right goods. The same has only turned more and more evident over the recent past, and a new FDA approval should do a lot to solidify its traces moving forward.

Fennec Pharmaceuticals, a medtech company based in North Carolina, has successfully earned FDA’s approval for its drug, Pedmark, which is designed to reduce the risk of hearing loss in patients receiving chemotherapy. Interestingly enough, the green light comes after two straight rejections, but now that it is here, the drug will be available for pediatric patients aged 1 month and older. Furthermore, these patients must be receiving a specific cisplatin-based chemotherapy for solid tumors that have not yet spread. The cisplatin, in general, is a platinum-centered therapy that can be used for treating a wide range of cancers. However, the toxic effects brought in to suffocate cancer cells have shown an additional tendency to spread across the body, and consequentially, cause serious side effects. Enter Fennec’s Pedmark. The drug is basically a proprietary formulation of sodium thiosulfate that interacts with cisplatin to produce an inactive form of platinum. Treating it as a launchpad, the drug goes on to spark activity across the relevant cells so to minimize the risk of chemo-induced hearing loss.

Fennec’s regulatory win is understood to come on the back of two open-label clinical trials. Boasting over 239 participants, these trials saw patients getting randomly assigned to receive either cisplatin, along with the Fennec drug dosed according to body weight, or just cisplatin alone. Both the trials proved that the prevalence of hearing loss was much lower in patients given Pedmark plus cisplatin compared to those treated with cisplatin alone.

“The FDA approval of PEDMARK represents an important breakthrough for pediatric patients with localized, non-metastatic solid tumors at risk for cisplatin-induced hearing loss. Cisplatin is a critical, standard of care agent, used in the treatment of pediatric cancers; however, even though effective, it could be harmful to children, frequently causing permanent and irreversible bilateral hearing loss. With PEDMARK, physicians now have an approved treatment option to reduce the risk of cisplatin-induced hearing loss in pediatric patients,” said Rosty Raykov, chief executive officer of Fennec Pharmaceuticals.

Must Read

Data Sciences in the Medical Industry: How powerful is it?

When novel compounds were researched about, to meet the needs of patients who were in critical conditions, medical science had huge growth....

Innovative Technologies Accelerating First-In-Human to Proof-of-Concept

During the earliest stages of clinical drug development, pharmaceutical and biotech companies need to make critical go / no-go decisions for their investigational products....

Developing Animal Free Organoid Models for Drug Discovery

There is an increasing drive within the pharmaceutical and personal care communities to reduce, if not eliminate, the use of animals in the testing...

Related News

Disrupting the Pharmaceutical Space Like Never Before

The human arsenal has a lot more to it than we usually acknowledge, and yet it doesn’t boast a feature more valuable than that...

Weaving a More Informed Healthcare Space

The human arsenal is known for a myriad of different things, but most importantly, it is known for getting better on a consistent basis....

Addressing a Big Old Plague

While the human arsenal has proven itself to be pretty much limitless, it still doesn’t possess anything more valuable than that tendency of ours...

Doubling Down on the Push to Enhance Mental Health

The human arsenal has always been a little on the loaded side, but if we being honest, it is still yet to possess anything...

Strengthening an Indispensible Pillar of Our Healthcare System

Human beings are known for many different things, but most importantly, we are known for getting better on a consistent basis. This tendency to...